|Dr. Jonathan C. Javitt||Co-Founder, Chairman & CEO||N/A||N/A||1957|
|Prof. Daniel C. Javitt||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. William V. Fricker||Chief Financial Officer||N/A||N/A||1965|
|Mr. Robert Besthof||Head of Operations & Chief Commercial Officer||N/A||N/A||N/A|
|Ms. Alessandra Daigneault Esq.||Gen. Counsel & Sec.||N/A||N/A||N/A|
|Mr. Jack Hirschfield||Sr. Director of Corp. Communications & External Affairs||N/A||N/A||N/A|
|Dr. Philip T. Lavin||Chief Methodologist||N/A||N/A||1947|
|Dr. Dennis K. McBride Ph.D.||Chief Strategy Officer & Sr. Scientist||N/A||N/A||N/A|
|Mr. Randolph Guggenheimer III||Chief Bus. Officer||N/A||N/A||N/A|
NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.
NRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.